Supplementary Tables and Figures

Table S1 – Characteristics comparing loss of follow-up and included patients
Table S2 – Comorbidities for COVID-19 and non-COVID-19 cases 3
Table S3 – Other symptoms reported by patients with long COVID
Table S4 – Sensitivity analysis of long COVID symptoms, adjusting for number of
comorbidities, BMI, respiratory allergy and smoking4
Table S5 – Assessment of quality of life using EuroQol instrument EQ-5D-3L 5
Figure S1 – Prevalence of SARS-CoV-2 variants of concern in Bahia during the study
period (from June, 2020, to April, 2021)7
Figure S2 – Questionnaire 1 8
Figure S3 – Questionnaire 2 10
Figure S4 – Questionnaire 3 12
Figure S5 – Diagram of the questionnaire application: time and data collected 13
Figure $S6$ – Time between residual symptoms call (questionnaire 3) and onset of
symptoms 14
Figure S7 – Correlation matrix with the frequency of residual symptoms of long COVID
patients 15
STROBE Statement – Checklist of items that should be included in reports of <i>cohort</i>
<i>studies</i>

Characteristic	Loss follow-up,	Study sample,	p-value*
	N = 455	N = 814	
Age - years; median (IQR)	37 (28-47)	35 (27-45)	0.10
Female sex	273 (60%)	487 (60%)	> 0.9
Body Mass Index kg/m ² (BMI);	26.0 (23.5-28.9)	26.5 (23.5-29.4)	0.4
median (IQR)			
Number of comorbidities			> 0.9
0	296 (65%)	535 (66%)	
1	110 (24%)	191 (23%)	
>1	49 (11%)	88 (11%)	
SARS-CoV-2			
Negative	217 (48%)	402 (49%)	0.6
Positive	238 (52%)	412 (51%)	
Required hospitalization / ICU			< 0.001
Hospitalization non-ICU	12 (2.6%)	65 (8.0%)	
(moderate)			
Hospitalization-ICU (severe)	5 (1.1%)	6 (0.7%)	

 $\label{eq:table_stable} Table \ S1-Characteristics \ comparing \ loss \ of \ follow-up \ and \ included \ patients.$

*Pearson's Chi-squared test; Wilcoxon rank sum test

Characteristic	Non-COVID-19	COVID-19	p-value*
	cases, $N = 402^{1}$	cases, N = 412 ¹	
Hypertension	45 (11%)	55 (13%)	0.3
Diabetes Mellitus	11 (2.7%)	12 (2.9%)	0.9
Cardiac disease	5 (1.2%)	10 (2.4%)	0.2
Chronic pulmonary	8 (2.0%)	5 (1.2%)	0.4
disease			
Cancer	2 (0.5%)	5 (1.2%)	0.5
Immunodeficiency	4 (1.0%)	2 (0.5%)	0.4
Previous stroke	1 (0.2%)	3 (0.7%)	0.6
Other	22 (5.5%)	17 (4.1%)	0.4
Smoking	43 (11%)	44 (11%)	> 0.9
Missing	4	5	

 Table S2 – Comorbidities for COVID-19 and non-COVID-19 cases.

*Pearson's Chi-squared test; Wilcoxon rank sum test

 Table S3 – Other symptoms reported by patients with long COVID.

Other reported residual symptoms	n (%)
Loss of memory	15 (12.3%)
Hair loss	9 (7.4%)
Joint pain	4 (3.3%)
Ear pain / ear disorder	4 (3.3%)

Table S4 – Sensitivity analysis of long COVID symptoms, adjusting for number ofcomorbidities, BMI, respiratory allergy and smoking.


Characteristic	Odds Ratio	95% CI	p-value
Female sex	1.56	0.99-2.49	0.059
Number of acute			
symptoms			
≤5			
> 5	3.46	1.48-9.54	0.008
Age group – years			
15 - 30			
31 - 40	1.66	0.91-3.06	0.10
41 - 50	2.07	1.02-4.24	0.044
> 50	2.24	1.13-4.48	0.021
BMI kg/m ² ; median	0.99	0.93-1.05	0.7
Number of comorbiditie	S		
0			
1	0.75	0.38-1.44	0.4
> 1	1.76	0.79-3.97	0.2
Respiratory allergy	1.32	0.78-2.21	0.3
Smoking	1.00	0.47-2.02	> 0.9

Quality of Life1	Long COVID	
Quality of Life ¹	n = 102	
Mobility		
I have no problems in walking about	94 (92.1%)	
I have some problems in walking about	8 (7.8%)	
I am confined to bed	0	
Self-care		
I have no problems with self-care	96 (94.1%)	
I have some problems washing or dressing myself	6 (5.9%)	
I am unable to wash or dress myself	0	
Usual activities		
I have no problems with performing my usual activities	73 (71.6%)	
I have some problems with performing my usual activities	28 (27.5%)	
I am unable to perform my usual activities	1 (0.9%)	
Pain / discomfort		
I have no pain or discomfort	60 (58.8%)	
I have moderate pain or discomfort	1 (0.9%)	

Table S5 – Assessment of quality of life using EuroQol instrument EQ-5D-3L.

I have extreme pain or discomfort	41 (40.2%)
Anxiety / depression	
I am not anxious or depressed	60 (58.8%)
I am moderately anxious or depressed	29 (28.4%)
I am extremely anxious or depressed	13 (12.7%)
Score global (IQR)	80 (70-90)

Figure S1 – Prevalence of SARS-CoV-2 variants of concern in Bahia during the study period (from June, 2020, to April, 2021).



Data obtained from the Fiocruz Genomic Network [11].

Figure S2 – Questionnaire 1

Qual(is) foi o sintoma(s) inicial(is)?

Falta de Ar
Febre
Tosse
Alteração recente ao sentir cheiros
Alteração recente ao sentir o gosto dos alimentos
Coriza
Espirro
Fraqueza
Dor no corpo
Diarreira
Enjoo
Vômito
Perda de Apetite
Dor nas articulações
Dor de cabeça
Outros

		; cabeça ;		
Sintomas apresentados até o mo	Sintomas apresentados até o momento			
	Não	Sim		
Falta de ar	0	0		
Nariz entupido	0	0		
Coriza	0	0		
Espirros	0	0		
Dor na garganta	0	0		
Dor na face	0	0		
Dor de cabeça	0	0		
Dor atrás dos olhos	0	0		
Dor no ouvido	0	0		
Dor muscular/no corpo	0	0		
Dor nas articulações/Dor nas juntas	0	0		
Dor no peito	0	0		
Dor na barriga	0	0		

Coriza	0	0
Espirros	0	0
Dor na garganta	0	0
Dor na face	0	0
Dor de cabeça	0	0
Dor atrás dos olhos	0	0
Dor no ouvido	0	0
Dor muscular/no corpo	0	0
Dor nas articulações/Dor nas juntas	0	0
Dor no peito	0	0
Dor na barriga	0	0
Manchas no corpo	0	0
Fraqueza no corpo	0	0
Desconforto no peito	0	0
Perda de Apetite	0	0
Enjoo	0	0
Vômitos	0	0
Diarreia (2 ou mais episódios nas últimas 48h)	0	0
Sensação de pressão baixa ou desmaio	0	0
Alteração recente ao sentir cheiros	0	0

Alteração recente ao sentir o gosto dos alimentos	0		0
Febre	0		0
Tosse	0		0
Data de início alteração no olfato			
Tempo em dias de alteração olfato			
Data de início alteração no paladar			
Tempo em dias alteração paladar			
Está usando algum medicamento pa	ara febre?	○ Não ○ Sim	
Qual medicamento para febre?			
Está usando algum medicamento pa	ara tosse?	○ Não ○ Sim	
Qual medicamento para tosse?			
Usa algum medicamento diariamen doença??	te/Tem alguma outra	○ Não ○ Sim	
i	Não sabe	Não	Sim
Corticoide Oral [Prednisona/Dexametasona/Pred nisolona]	0	0	0
Inibidor de bomba de Próton [Omeprazol/Pantoprazol/Iansopr azol]	0	0	0
AINES [Aspirina/Ibuprofeno/Diclofenaco /Nimesulida/Meloxicam]	0	0	0
Outros medicamentos	0	0	0
Qual outro medicamento ? Listar separado por vírgula			

IMC

Realizou exame para confirmação de infecção por COVID-19?	○ Não ○ Sim
Resultado PCR	 Negativo Positivo Não realizado Inconclusivo
Data do PCR	
Tempo pós-sintomas do PCR	
Resultado ELISA/Teste Rápido	 ○ Negativo ○ Positivo ○ Não realizado
Data do ELISA/Teste Rápido	
Tempo pós-sintomas do ELISA	
g ure S3 – questionnaire 2	

Conseguiu realizar a Ligação de seguimento	○ Não ○ Sim	
Data da tentativa		
Motivo	 ○ Não atendeu ○ Número incorreto ○ Outro 	
Qual motivo		
Data da ligação de retorno		
Tempo pós sintomas da ligação de retorno		
Necessidade de internação hospitalar?	⊖ Não ⊖ Sim	
Internação	🔿 Ala/Enfermaria 🛛 UTI	
UTI	 Sem ventilação mecânica Com ventilação mecânica 	
Situação atual	○ Saudável ○ Alguma sequela pós-covid ○ Óbito	

Sintomas relatados na fase aguda

Sintomas durante o período da doença	э.			
Marcar os já relatados e qualquer novo	0			
5.1	Não		Sim	
Febre	0		0	
Tosse	0		0	
Falta de ar	0		0	
Nariz entupido	0		0	
Coriza	0		0	
Espirros	0		0	
Dor na garganta	0		0	
Dor na face	0		0	
Dor de cabeça	0		0	
Dor atrás dos olhos	0		0	
Dor no ouvido	0		0	
Dor muscular/no corpo	0		0	
Dor nas articulações/Dor nas juntas	0		0	
Realizado Ligação de acompanhameno de sec	quelas?	○ Não ○ Sim		
Data da ligação de acompanhamento				
Você sente/tem algum sintoma hoje?		○ Não ○ Sim		
Tempo pós sintomas da ligação de sequela				
Sintomas presentes no momento da				
	Não		Sim	
Febre Atual	0		0	
Tosse Atual	0		0	
Fadiga Atual	0		0	
Ealta do ar Atual	\cap		\circ	

Falta de ar Atual O 0 0 Dor de cabeça Atual 0 Ο Dor no peito atual 0 Ο Dor muscular/no corpo Atual 0 0 Falta de apetite Atual 0 Ο Dificuldade de engolir (Atual) Ο Ο Dificuldade para falar (Atual) 0 Ο Alteração recente ao sentir cheiros (Atual) Alteração recente ao sentir o gosto dos alimentos (Atual) Ο Ο ○ Não ○ Sim Outro sintoma persistente: Qual outro sintoma

Vômitos	0	0
Diarreia (2 ou mais episódios nas últimas 48h)	0	0
Sensação de pressão baixa ou desmaio	0	0
Alteração recente ao sentir cheiros	0	0
Alteração recente ao sentir o gosto dos alimentos	0	0

Figure S4 – questionnaire 3

Realizado Ligação de acompanhameno de sequelas?	○ Não ○ Sim	
Data da ligação de acompanhamento		
Você sente/tem algum sintoma hoje?	○ Não ○ Sim	
	_	

Tempo pós sintomas da ligação de sequela

Sintomas presentes no momento da ligação		
	Não	Sim
Febre Atual	0	0
Tosse Atual	0	0
Fadiga Atual	0	0
Falta de ar Atual	0	0
Dor de cabeça Atual	0	0
Dor no peito atual	0	0
Dor muscular/no corpo Atual	0	0
Falta de apetite Atual	0	0
Dificuldade de engolir (Atual)	0	0
Dificuldade para falar (Atual)	0	0
Alteração recente ao sentir cheiros (Atual)	0	0
Alteração recente ao sentir o gosto dos alimentos (Atual)	0	0
Outro sintoma persistente:	○ Não ○ Sim	

Qual outro sintoma




Figure S5 – Diagram of the questionnaire application: time and data collected.

Figure created with BioRender. Available: https://biorender.com. Accessed: 28 April

2023.




Figure S6 – Time between residual symptoms call (questionnaire 3) and onset of symptoms.




Figure S7 – Correlation matrix with the frequency of residual symptoms of long COVID patients.

STROBE Statement — Checklist of items that should be included in reports of *cohort studies*

	Item	
	No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the
		title or the abstract – section title
		(b) Provide in the abstract an informative and balanced summary of
		what was done and what was found – section abstract
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation
		being reported – section Background paragraph 1
Objectives	3	State specific objectives, including any prespecified hypotheses – section Background paragraph 2
Methods		
Study design	4	Present key elements of study design early in the paper – section
		Methods paragraphs 1-5
Setting	5	Describe the setting, locations, and relevant dates, including periods
		of recruitment, exposure, follow-up, and data collection – section
		Methods paragraphs 1-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up – section
		Methods paragraph 1
		(b) For matched studies, give matching criteria and number of
		exposed and unexposed – not appliable
Variables	7	Clearly define all outcomes, exposures, predictors, potential
		confounders, and effect modifiers. Give diagnostic criteria, if
-		applicable – section Methods paragraphs 6-7
Data sources/	8*	For each variable of interest, give sources of data and details of
measurement		methods of assessment (measurement). Describe comparability of
		assessment methods if there is more than one group – section
		Methods paragraphs 6-7
Bias	9	Describe any efforts to address potential sources of bias – section Methods paragraph 4
Study size	10	Explain how the study size was arrived at – not appliable
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If
Quantitati (C) and a co		applicable, describe which groupings were chosen and why – section
		Methods paragraph 8
Statistical methods	12	(<i>a</i>) Describe all statistical methods, including those used to control
		for confounding - section Methods paragraph 8
		(b) Describe any methods used to examine subgroups and
		interactions – not appliable
		(c) Explain how missing data were addressed – not appliable
		(d) If applicable, explain how loss to follow-up was addressed $-$ not
		appliable
		(<u>e</u>) Describe any sensitivity analyses – section Methods paragraph
		8
Results		
Participants	1.0*	(a) Report numbers of individuals at each stage of study—eg
1 articipants	13*	
1 articipants	13*	numbers potentially eligible, examined for eligibility, confirmed
i articipants	13*	
i articipants	13*	numbers potentially eligible, examined for eligibility, confirmed
i articipants	13*	numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed –
i articipants	13*	numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – section Results paragraph 1
i articipants	13*	numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – section Results paragraph 1 (b) Give reasons for non-participation at each stage – section
-	13*	numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – section Results paragraph 1 (b) Give reasons for non-participation at each stage – section Results paragraph 1
Descriptive data		numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed – section Results paragraph 1 (b) Give reasons for non-participation at each stage – section Results paragraph 1 (c) Consider use of a flow diagram – Fig. 1

		(b) Indicate number of participants with missing data for each variable of interest – section Results paragraph 1 / Additional file 1: Table S1
		(c) Summarise follow-up time (eg, average and total amount) – section Results paragraph 1 / Additional file 1: Fig.3
Outcome data	15*	Report numbers of outcome events or summary measures over time – section Results paragraphs 2,3
Main results	16	 (a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included – section Results paragraphs 4,5
		(b) Report category boundaries when continuous variables were categorized
		(<i>c</i>) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period – not appliable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses – not appliable
Discussion		
Key results	18	Summarise key results with reference to study objectives – section Discussion paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias – section Discussion paragraph 7
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence – section Discussion paragraphs 2-6
Generalisability	21	Discuss the generalisability (external validity) of the study results – section Discussion paragraph 6 and conclusions
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based – section Declarations (funding)

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.